Fennec announces planned initiation of IST by City of Hope to evaluate PEDMARK

Fennec (FENC) Pharmaceuticals announced the planned initiation of an investigator-sponsored study, IST, by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK for the prevention of cisplatin-induced ototoxicity, CIO, in adult men with stage II-III metastatic testicular germ cell tumors. “Initiation of this study by City of Hope reflects the growing clinical interest in addressing the burden of hearing loss among patients receiving cisplatin-based chemotherapy, an indispensable treatment with high survival rates but significant long-term quality-of-life consequences,” said Pierre S. Sayad, PhD, M.S., chief medical officer of Fennec Pharmaceuticals. “With cancer rates rising, especially among younger populations, the future of oncological care needs to focus on both survival and survivorship. Fennec is proud to see independent investigators driving important research that not only has the potential to change the standard of care for their patients today but also expand the evidence base for PEDMARK into metastatic disease, where cisplatin is widely used but hearing protection options remain limited.”